Showing results (591-600 of 963) with videos related to

Sort By:
Pageof 97
Transplantation Direct|October 3, 2019
Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017Angus W Jeffrey, Luc Delriviere, Geoff McCaughan, et al.
Annals of the New York Academy of Sciences|August 4, 2015
Development of sofosbuvir for the treatment of hepatitis C virus infectionEric Lawitz, Ira M Jacobson, David R Nelson, et al.
Bioorganic & Medicinal Chemistry|December 3, 2014
2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretionJames R Sayer, Karin Walldén, Thomas Pesnot, et al.
Functional & Integrative Genomics|April 16, 2015
Wild soybean roots depend on specific transcription factors and oxidation reduction related genesin response to alkaline stressHuizi DuanMu, Yang Wang, Xi Bai, et al.
Viruses|May 28, 2022
Isolation of a Human Betaretrovirus from Patients with Primary Biliary CholangitisMariam Goubran, Weiwei Wang, Stanislav Indik, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 11, 2018
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis BDarren Wong, Margaret Littlejohn, Rosalind Edwards, et al.
Journal of Viral Hepatitis|August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)S D Shafran, D Shaw, M Charafeddine, et al.
Cells|June 10, 2022
Therapeutic Validation of GEF-H1 Using a De Novo Designed Inhibitor in Models of Retinal DiseaseClare Mills, Sandra A Hemkemeyer, Zerin Alimajstorovic, et al.
Hepatology (Baltimore, Md.)|April 5, 2012
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II studyMichael P Manns, Edward Gane, Maribel Rodriguez-Torres, et al.
Journal of Gastroenterology|March 15, 2019
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infectionAtsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, et al.
Pageof 97